Helus Pharma (NASDAQ: HELP) (Cboe CA: HELP) has announced a collaboration with TARA Mind, working alongside Veterans Exploring Treatment Solutions (VETS), to support clinical trial recruitment for its PARADIGM HLP003 Phase 3 program targeting major depressive disorder. The partnership also aims to expand mental health awareness within the veteran community. By leveraging the networks of TARA Mind and VETS, the collaboration seeks to enhance veteran engagement in the trial, which is investigating HLP003, a proprietary novel serotonergic agonist (NSA) that has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration.
The announcement aligns with the April 18, 2026 Executive Order on accelerating treatments for serious mental illness, underscoring the importance of advancing therapies for conditions like major depressive disorder. Helus Pharma is focused on developing NSAs—synthetic molecules designed to activate serotonin pathways believed to promote neuroplasticity. The company's pipeline includes HLP003 in Phase 3 for major depressive disorder and HLP004 in Phase 2 for generalized anxiety disorder, along with an extensive research portfolio of investigational NSAs.
The partnership with TARA Mind and VETS is expected to facilitate recruitment by tapping into existing networks that serve veterans, a population disproportionately affected by mental health conditions. This collaboration reflects a broader effort to address the large unmet need for individuals suffering from depression, anxiety, and other mental health issues. Helus Pharma, operating as the commercial name of Cybin Inc., aims to improve the treatment landscape through the introduction of NSAs that provide durable improvements in mental health.
For more information about Helus Pharma and its pipeline, visit the company's website at www.helus.com. The latest news and updates regarding HELP are available in the company's newsroom at https://ibn.fm/HELP. This partnership highlights the ongoing efforts to leverage community-based organizations to enhance clinical trial participation and address mental health challenges among veterans.
